In milk fermented with
Lactobacillus helveticus, a lactic acid bacterium with potent proteolytic activity, valyl-prolyl-proline and isoleucyl-prolyl-proline are produced. These two peptides have been shown to have an inhibitory effect on angiotensin-converting enzyme, which converts angiotensin I to angiotensin II, a strong vasoconstrictor. Pre-clinical and
in vitro studies suggest an orally ingested dose of these peptides can be absorbed in an intact form from the gastrointestinal tract, and can inhibit the renin-angiotensin system, producing significant reductions in blood pressure. In our human studies, fermented milk containing these peptides significantly decreased systolic and diastolic blood pressure in hypertensive subjects. Inhibitors of angiotensin-converting enzyme increase bradykinin, which in turn increases nitric oxide production, improving endothelial function. These peptides improved acetylcholine-induced vascular reactivity in rats administered NG-nitro-L-arginine methyl ester hydrochloride, an inhibitor of nitric oxide production. Furthermore, we measured the reactive hyperemia of the human upper forearm using plethysmography as an index of vascular endothelial function, and observed that casein hydrolysate containing the peptides significantly increased the forearm blood flow with no change in systemic blood pressure, indicating the improvement in vascular endothelial function, attributable to the tripeptides, was independent of hemodynamic changes. These results suggest that valyl-prolyl-proline and isoleucyl-prolyl-proline contribute to reducing the risk of metabolic syndrome by modulating vascular endothelial function as well as blood pressure.
View full abstract